이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

성인 진행성 고형암 환자를 대상으로 한 IDE574 요법의 안전성, 약동학 및 예비 효능에 관한 연구

2026년 11월 2일 업데이트: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

연구 개요

상세 설명

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

연구 유형

중재적

등록 (추정된)

155

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, 그루지야, 6000
        • 모병
        • High Technology Hospital MedCenter Ltd
        • 수석 연구원:
          • Tamta Makharadze, MD
        • 연락하다:
      • Tbilisi, K'alak'i T'bilisi, 그루지야, 114
        • 모병
        • Pineo Medical Ecosystem
        • 연락하다:
        • 수석 연구원:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, 그루지야, 112
        • 모집하지 않고 적극적으로
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, 그루지야, 144
        • 모집하지 않고 적극적으로
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, 그루지야, 186
        • 모집하지 않고 적극적으로
        • LLC Caucasus Medical Centre
    • California
      • Santa Monica, California, 미국, 90404-2095
        • 모집하지 않고 적극적으로
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, 미국, 06510-3206
        • 모병
        • Yale School of Medicine - Cedar Street
        • 수석 연구원:
          • Patricia LoRusso, MD
        • 연락하다:
    • Florida
      • Plantation, Florida, 미국, 33322
        • 모병
        • Florida Clinical Trials Group
        • 수석 연구원:
          • Harshad Amin, MD
        • 연락하다:
    • Georgia
      • Atlanta, Georgia, 미국, 30322-1013
        • 모병
        • Winship Cancer Institute, Emory University
        • 수석 연구원:
          • Shipra Gandhi, MD
        • 연락하다:
    • Missouri
      • St Louis, Missouri, 미국, 63110-1010
        • 모병
        • Washington University - Siteman Cancer Center
        • 수석 연구원:
          • Faisal Fa'ak, MD
        • 연락하다:
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • 모병
        • START Astera, LLC
        • 수석 연구원:
          • Bruno Fang, MD
        • 연락하다:
    • New York
      • Lake Success, New York, 미국, 11042
        • 모병
        • START New York Long Island, LLC
        • 수석 연구원:
          • Geraldine O'Sullivan Coyne, MD
        • 연락하다:
      • New York, New York, 미국, 10032-3729
        • 모집하지 않고 적극적으로
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • SCRI Oncology Partners - PPDS
        • 수석 연구원:
          • Sarah Premji, MD
        • 연락하다:
    • Texas
      • Austin, Texas, 미국, 78758
      • Dallas, Texas, 미국, 75039
      • Fort Worth, Texas, 미국, 76104
        • 모병
        • START Dallas Fort Worth, LLC
        • 수석 연구원:
          • Henry Xiong, MD
        • 연락하다:
      • Houston, Texas, 미국, 77030-4009
        • 모병
        • MD Anderson Cancer Center
        • 수석 연구원:
          • Timothy Yap, MD
        • 연락하다:
      • Houston, Texas, 미국, 77054
      • San Antonio, Texas, 미국, 78229
        • 모병
        • NEXT Texas LLC - San Antonio
        • 수석 연구원:
          • David Sommerhalder, MD
        • 연락하다:
      • San Antonio, Texas, 미국, 78229
        • 모병
        • Start San Antonio, LLC
        • 수석 연구원:
          • Amita Patnaik, MD
        • 연락하다:
    • Utah
      • West Valley City, Utah, 미국, 84119
        • 모병
        • START Mountain Region, LLC
        • 수석 연구원:
          • William McKean, MD
        • 연락하다:
    • Virginia
      • Fairfax, Virginia, 미국, 22031

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

실험적: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

실험적: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

실험적: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
기간: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
기간: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
기간: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
기간: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
기간: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
기간: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
기간: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
기간: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

2차 결과 측정

결과 측정
기간
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
기간: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
기간: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
기간: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
기간: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
기간: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
기간: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
기간: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
기간: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
기간: total study duration
total study duration

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 17일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2030년 1월 31일

연구 등록 날짜

최초 제출

2026년 4월 1일

QC 기준을 충족하는 최초 제출

2026년 4월 14일

처음 게시됨 (실제)

2026년 4월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다